Escaping immune surveillance in cancer: Is denbinobin the panacea?

British Journal of Pharmacology

Volumn 157, Issue 7, 2009, Pages 1172-1174

  Magwere, Tapiwanashe ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Cancer; Death receptor; Decoy receptor; Denbinobin; Fas ligand; Immune surveillance; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; DECOY RECEPTOR 3; DENBINOBIN; FAS LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER RESEARCH; CANCER THERAPY; COLON CANCER; DENDROBIUM; NONHUMAN; NOTE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION;

ADENOCARCINOMA; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; FAS LIGAND PROTEIN; HUMANS; PANCREATIC NEOPLASMS; PHENANTHRENES; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; TUMOR ESCAPE;

EID: 70350344037     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00286.x     Document Type: Note

References (12)

1. Ashkenazi A, Dixit VM (1998). Death receptors: signaling and modulation. Science 281 (5381): 1305-1308
2. Ashkenazi A, Dixit VM (1999). Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11 (2): 255-260
3. Kuo CT, Hsu MJ, Chen BC, Chen CC, Teng CM, Pan SL et al. (2008). Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction. Toxicol Lett 177 (1): 48-58
4. Lee YH, Park JD, Baek NI, Kim SI, Ahn BZ (1995). In vitro and in vivo antitumoral phenanthrenes from the aerial parts of Dendrobium nobile. Planta Med 61 (2): 178-180
5. O'Reilly EM, Abou-Alfa GK (2007). Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 34 (4): 347-353
6. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364 (6440): 806-809
7. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P et al. (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396 (6712): 699-703
8. Swann JB, Smyth MJ (2007). Immune surveillance of tumors. J Clin Invest 117 (5): 1137-1146
9. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M et al. (2002). The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5 (2): 61-68
10. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S et al. (2003). Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adeno-carcinoma. Int J Cancer 106 (1): 17-25
11. Yang CR, Guh JH, Teng CM, Chen CC, Chen PH (2009). Combined treatment with Denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells. Br J Pharmacol 157: 1175-1185
12. Yang KC, Uen YH, Suk FM, Liang YC, Wang YJ, Ho YS et al. (2005). Molecular mechanisms of denbinobin-induced anti-tumorigenesis effect in colon cancer cells. World J Gastroenterol 11: 3040-3045